Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.
Merck Wards Off More Januvia Infringers In India
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.
More from Alimentary/Metabolic
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.